​

Eli Lilly (LLY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LLY Stock Forecast

Eli Lilly (LLY) stock forecast, based on 45 Wall Street analysts, predicts a 12-month average price target of $1,244.68, with a high of $1,350.00 and a low of $985.00. This represents a 40.81% increase from the last price of $883.96.

$550 $710 $870 $1 $1 $1 High: $1350 Avg: $1244.68 Low: $985 Last Closed Price: $883.96

LLY Stock Rating

Eli Lilly stock's rating consensus is Buy, based on 45 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 33 Buy (73.33%), 9 Hold (20.00%), 3 Sell (6.67%), and 0 Strong Sell (0.00%).

Buy
Total 45 0 3 9 33 Strong Sell Sell Hold Buy Strong Buy

LLY Price Target Upside V Benchmarks

TypeNameUpside
StockEli Lilly40.81%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks14.15%

Price Target Trends

1M3M12M
# Anlaysts11235
Avg Price Target$1.33K$1.29K$1.13K
Last Closing Price$883.96$883.96$883.96
Upside/Downside50.12%45.61%28.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2661861-31
Mar, 266186-131
Feb, 264177-129
Jan, 264187-130
Dec, 254178-130
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 10, 2026Morgan Stanley$1.33K$939.3141.27%50.12%
Mar 13, 2026Akash TewariJefferies$1.30K$1.00K29.90%47.07%
Mar 06, 2026James ShinDeutsche Bank$1.28K$990.3129.76%45.37%
Mar 05, 2026Terence FlynnMorgan Stanley$1.31K$972.5035.01%48.54%
Feb 24, 2026Trung HuynhRBC Capital$1.25K$1.04K19.94%41.41%
Feb 19, 2026Barclays$1.35K$1.02K31.94%52.72%
Feb 10, 2026Ilya ZubkovLoop Capital Markets$1.20K$1.02K17.07%35.75%
Feb 05, 2026Scotiabank$1.30K$1.04K25.35%47.07%
Feb 05, 2026Truist Financial$1.28K$1.03K24.67%44.92%
Feb 05, 2026Goldman Sachs$1.26K$1.11K13.81%42.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 10, 2026Morgan StanleyOverweightOverweighthold
Mar 18, 2026UBSBuyBuyhold
Mar 16, 2026RBC CapitalOutperformOutperformhold
Mar 13, 2026JefferiesBuyBuyhold
Mar 10, 2026BernsteinOutperformOutperformhold
Mar 06, 2026Deutsche BankBuyBuyhold
Mar 05, 2026Morgan StanleyOverweightOverweighthold
Feb 24, 2026RBC CapitalOutperforminitialise
Feb 24, 2026Bank of America SecuritiesBuyBuyhold
Feb 19, 2026BarclaysOverweightOverweightinitialise

Financial Forecast

EPS Forecast

$5 $13 $21 $29 $37 $45 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.85$6.57$5.83$11.76$23.00---
Avg Forecast$8.13$7.64$6.23$12.95$22.49$29.14$34.70$41.01
High Forecast$9.04$8.56$6.58$13.35$27.77$33.34$41.05$43.17
Low Forecast$7.42$6.99$5.86$12.41$21.13$23.61$25.96$39.12
Surprise %-28.04%-14.01%-6.42%-9.19%2.27%---

Revenue Forecast

$25B $39B $53B $67B $81B $95B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$28.32B$28.54B$34.12B$45.04B$65.18B---
Avg Forecast$28.04B$28.59B$33.65B$45.31B$58.51B$70.05B$79.12B$89.33B
High Forecast$30.46B$31.25B$33.90B$45.68B$59.01B$70.10B$79.63B$92.95B
Low Forecast$26.15B$26.74B$33.44B$45.00B$58.02B$70.00B$78.61B$86.17B
Surprise %0.99%-0.17%1.40%-0.58%11.41%---

Net Income Forecast

$0 $8B $16B $24B $32B $40B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.58B$6.24B$5.24B$10.59B$20.64B---
Avg Forecast$5.76B$5.98B$5.24B$11.63B$19.44B$24.80B$30.38B$37.04B
High Forecast$6.92B$7.17B$6.29B$12.06B$25.08B$30.11B$37.08B$39.00B
Low Forecast$4.61B$4.78B$4.19B$11.21B$19.09B$21.33B$23.45B$35.34B
Surprise %-3.15%4.45%--8.95%6.14%---

LLY Forecast FAQ

Is Eli Lilly stock a buy?

Eli Lilly stock has a consensus rating of Buy, based on 45 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 33 Buy, 9 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Eli Lilly is a favorable investment for most analysts.

What is Eli Lilly's price target?

Eli Lilly's price target, set by 45 Wall Street analysts, averages $1.24K over the next 12 months. The price target range spans from $985 at the low end to $1.35K at the high end, suggesting a potential 40.81% change from the previous closing price of $883.96.

How does Eli Lilly stock forecast compare to its benchmarks?

Eli Lilly's stock forecast shows a 40.81% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (14.15%).

What is the breakdown of analyst ratings for Eli Lilly over the past three months?

  • April 2026: 19.35% Strong Buy, 58.06% Buy, 19.35% Hold, 3.23% Sell, 0% Strong Sell.
  • March 2026: 19.35% Strong Buy, 58.06% Buy, 19.35% Hold, 0% Sell, 3.23% Strong Sell.
  • February 2026: 13.79% Strong Buy, 58.62% Buy, 24.14% Hold, 0% Sell, 3.45% Strong Sell.

What is Eli Lilly’s EPS forecast?

Eli Lilly's average annual EPS forecast for its fiscal year ending in December 2026 is $29.14, marking a 26.70% increase from the reported $23 in 2025. Estimates for the following years are $34.7 in 2027, and $41.01 in 2028.

What is Eli Lilly’s revenue forecast?

Eli Lilly's average annual revenue forecast for its fiscal year ending in December 2026 is $70.05B, reflecting a 7.48% increase from the reported $65.18B in 2025. The forecast for 2027 is $79.12B, and $89.33B for 2028.

What is Eli Lilly’s net income forecast?

Eli Lilly's net income forecast for the fiscal year ending in December 2026 stands at $24.8B, representing an 20.17% increase from the reported $20.64B in 2025. Projections indicate $30.38B in 2027, and $37.04B in 2028.